| Filed On | Filing |
|---|---|
| 23 Apr 2026 |
Proxy statement: annual meeting on June 11, 2026
CEO pay $13.0M, up 56% · say-on-pay vote |
| 24 Apr 2025 |
Proxy statement: annual meeting on June 12, 2025
CEO pay $8.3M, up 74% · say-on-pay vote |
| 25 Apr 2024 |
DEF 14A
CEO pay $4.8M, down 32% |
| 27 Apr 2023 |
DEF 14A
CEO pay $7.0M, down 1.1% |
| 25 Apr 2022 | DEF14A |
| 13 Apr 2021 | FORM DEF 14A |
| 31 Mar 2020 | DEFINITIVE PROXY STATEMENT |
| 17 Apr 2019 | DEF 14A |
| 28 Sep 2018 | DEF 14A |
| 10 May 2018 | DEFINITIVE PROXY STATEMENT |
| 12 Apr 2017 | DEFINITIVE PROXY STATEMENT |
| 11 Apr 2016 | DEFINITIVE PROXY STATEMENT |
| 10 Apr 2015 | DEFINITIVE PROXY STATEMENT |
| 21 Mar 2014 | DEF 14A |
| 16 Apr 2013 | DEF 14A |
| 09 Apr 2012 | NOTICE AND PROXY |
| 05 Apr 2011 | DEF 14A |
| 06 Apr 2010 | DEF 14A |
| 03 Apr 2009 | DEF 14A |
| 16 Apr 2008 | BIOCRYST PHARMACEUTICALS, INC. |
Loading...
